Reneo Pharmaceuticals, Inc.

NASDAQ:RPHM

1.82 (USD) • At close October 4, 2024
Bedrijfsnaam Reneo Pharmaceuticals, Inc.
Symbool RPHM
Munteenheid USD
Prijs 18.2
Beurswaarde 60,840,416
Dividendpercentage 0%
52-weken bereik 1.68 - 82.9
Industrie Biotechnology
Sector Healthcare
CEO Mr. Gregory J. Flesher
Website https://reneopharma.com

An error occurred while fetching data.

Over Reneo Pharmaceuticals, Inc.

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical

Vergelijkbare Aandelen

Aligos Therapeutics, Inc. logo

Aligos Therapeutics, Inc.

ALGS

38.85 USD

Vaccinex, Inc. logo

Vaccinex, Inc.

VCNX

1.31 USD

Daxor Corporation logo

Daxor Corporation

DXR

8.3 USD

Sensei Biotherapeutics, Inc. logo

Sensei Biotherapeutics, Inc.

SNSE

0.452 USD

Cardiff Oncology, Inc. logo

Cardiff Oncology, Inc.

CRDF

4.07 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)